Aim: To investigate whether the estimation of cerebrospinal fluid (CSF) and brain YKL-40 levels may be used as an efficient biomarker for Parkinson's disease (PD). Methods: Lipopolysaccharides (LPS) was injected into the right substantia nigra pars compacta (SNpc). Rats were divided into: control group, early LPS-induced PD group (14 days), and advanced LPS-induced PD group (28 days). YKL-40 and other related factors were detected in CSF and brain tissue. Results: Increased expression of YKL-40 was observed in brain tissue and CSF of PD-induced rats associated with triggered inflammatory cytokine release. Conclusion: The current study was limited to detecting YKL-40 and other inflammatory factors in brain and CSF. YKL-40 may be considered as an early biomarker and therapeutic target for PD.
Keywords: Parkinson's disease; YKL-40; amyloid beta; lipopolysaccharides; microglia; neuroinflammation.
Parkinson's disease (PD) is one of the most devastating fast-spreading neurological disorders with a high prevalence and incidence of death. Progress in developing efficient therapeutic interventions in PD may only be achieved through reliable early diagnostic approaches along with regular monitoring of PD progression. Although the current clinical diagnostic approach to PD relies mainly on late motor symptoms, the rate of misdiagnosis is considered high due to the overlap of PD with other etiologies. Novel and reliable biological biomarkers are highly required among researchers with the aim of early detection of the disease pathogenesis during the premotor stages to avoid debilitating PD stages. Thereby, identifying and highlighting novel biological biomarkers are highly required in the early diagnosis of neurological disorders.